A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2012 Additional location (France) added as reported by European Clinical Trials Database.
- 27 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History